Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 7, No. 3, 1998
Issue release date: July – September
Section title: Case Report

Open Access Gateway

Med Principles Pract 1998;7:215–222

Rising Incidence of Beta-Lactam Resistance among Pneumococci in Kuwait: Failure of Cefotaxime Therapy in Pneumococcal Meningitis

Johny M.a · Narayanan S.b · Murad M.A.a
Departments of a Laboratory Medicine and b Medicine, Al-Amiri Hospital, Ministry of Public Health, Kuwait
email Corresponding Author

Dr. Molly Johny

Microbiology Unit, Department of Laboratory Medicine

Al-Amiri Hospital, PO Box 4077

13041 Safat (Kuwait)

Fax +965 2465299

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Objective: Pneumococcal resistance to antimicrobial agents has become a global problem. This study was done to evaluate the resistance of Streptococcus pneumoniae (pneumococci) to penicillin G in Kuwait, and to assess the efficacy of other β-lactam agents (cefotaxime or ceftriaxone) in the management of invasive pneumococcal infections. Methods: Surveillance studies were done in a general teaching hospital in Kuwait for penicillin G resistance (intermediate or high level resistance) of pneumococci isolated from clinical specimens by agar diffusion method using oxacillin (1 µg) disc. In cases of pneumococcal meningitis, minimum inhibitory concentrations (MICs) of penicillin and cefotaxime were determined by agar dilution method, to differentiate intermediate resistance and high level resistance. Results: An increase in the incidence of penicillin G-resistant pneumococci from 20.6% (94 out of 457 isolates) for the period 1985–1988 to 28.5% (40 out of 140 isolates) during 1992–1994 and 38.3% (43 out of 112 isolates) during 1995/96 was observed. During the period 1992–1994, 40–45% (7 out of 16 isolates) blood culture isolates of pneumococci were intermediate or highly resistant to penicillin. Therapy with cefotaxime or ceftriaxone produced a positive outcome in 6 of the 7 patients. However, failure of cefotaxime therapy to achieve a cure was noted in 1 patient who had systemic lupus erythematosus and intermediate resistant (penicillin MIC 0.5 mg/l; cefotaxime MIC 1 mg/l) pneumococcal septicaemia complicated with meningitis. A cure was however achieved with the addition of chloramphenicol to the regimen. Conclusion: Resistance of pneumococci to penicillin G and other β-lactam agents is increasing in Kuwait. Penicillin-resistant pneumococcal bacteraemia in an immunosuppressed setting, if managed with cefotaxime or ceftriaxone, should be given high doses (cefotaxime 12 g/day or ceftriaxone 4 g/day) from the beginning. Cases of pneumococcal meningitis with cefotaxime-intermediate resistant strains (MIC 0.5–1 mg/l) on monotherapy consisting of cefotaxime or ceftriaxone should be viewed with caution. Chloramphenicol or vancomycin with rifampicin should be added to the regimen if therapeutic failure is suspected.

Article / Publication Details

First-Page Preview
Abstract of Case Report

Published online: September 18, 1998
Issue release date: July – September

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 3

ISSN: 1011-7571 (Print)
eISSN: 1423-0151 (Online)

For additional information: http://www.karger.com/MPP

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.